Michael Rieder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11047488/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Paediatric pharmacotherapy and drug regulation: Moving past the therapeutic orphan. British Journal of Clinical Pharmacology, 2022, 88, 4250-4257.	2.4	10
2	L'amélioration des médicaments à usage pédiatrique : une prescription pour les enfants et les adolescents canadiens. Paediatrics and Child Health, 2019, 24, 336-339.	0.6	0
3	Pharmacy and pediatric drug therapy: The key to safe and effective treatment for children. American Journal of Health-System Pharmacy, 2019, 76, 1452-1453.	1.0	4
4	Improving paediatric medications: A prescription for Canadian children and youth. Paediatrics and Child Health, 2019, 24, 333-335.	0.6	18
5	Adverse Drug Reactions in Children: Pediatric Pharmacy and Drug Safety. Journal of Pediatric Pharmacology and Therapeutics, 2019, 24, 4-9.	0.5	22
6	Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children. Pharmaceutical Medicine, 2018, 32, 21-30.	1.9	5
7	Adverse Drug Reactions Across the Age Continuum: Epidemiology, Diagnostic Challenges, Prevention, and Treatments. Journal of Clinical Pharmacology, 2018, 58, S36-S47.	2.0	20
8	Averting the foul taste of pediatric medicines improves adherence and can be lifesaving – Pheburane® (sodium phenylbutyrate). Patient Preference and Adherence, 2016, Volume 10, 2141-2144.	1.8	6
9	Design and conduct of early phase drug studies in children: challenges and opportunities. British Journal of Clinical Pharmacology, 2016, 82, 1308-1314.	2.4	21
10	Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children. Pediatric Research, 2015, 78, 44-47.	2.3	20
11	Do we prescribe medicines rationally?. Archives of Disease in Childhood, 2015, 100, 958-959.	1.9	3
12	The Detection of Cortisol in Human Sweat. Therapeutic Drug Monitoring, 2014, 36, 30-34.	2.0	132
13	How sweet it isn't: a new formulation of sodium phenylbutyrate and the challenge of palatability for medicines for children. Archives of Disease in Childhood, 2012, 97, 1080-1080.	1.9	8
14	Development of Drugs from Plants. Advances in Botanical Research, 2012, 62, 385-408.	1.1	0
15	New Ways to Detect Adverse Drug Reactions in Pediatrics. Pediatric Clinics of North America, 2012, 59, 1071-1092.	1.8	22
16	More Codeine Fatalities After Tonsillectomy in North American Children. Pediatrics, 2012, 129, e1343-e1347.	2.1	334
17	Hair cortisol as a biological marker of chronic stress: Current status, future directions and unanswered questions. Psychoneuroendocrinology, 2012, 37, 589-601.	2.7	769
18	Hair cortisol content in patients with adrenal insufficiency on hydrocortisone replacement therapy. Clinical Endocrinology, 2011, 74, 687-693.	2.4	50

MICHAEL RIEDER

#	Article	IF	CITATIONS
19	The effect of <i>N</i> -acetylcysteine on the antitumor activity of ifosfamide. Canadian Journal of Physiology and Pharmacology, 2011, 89, 335-343.	1.4	6
20	Hair cortisol and the risk for acute myocardial infarction in adult men. Stress, 2011, 14, 73-81.	1.8	128
21	Assessing individual systemic stress through cortisol analysis of archaeological hair. Journal of Archaeological Science, 2010, 37, 807-812.	2.4	89
22	If children ruled the pharmaceutical industry: The need for pediatric formulations. Drug News and Perspectives, 2010, 23, 458.	1.5	31
23	Testosterone Concentrations in Hair of Hypogonadal Men With and Without Testosterone Replacement Therapy. Therapeutic Drug Monitoring, 2009, 31, 779-782.	2.0	16
24	Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert Opinion on Drug Safety, 2009, 8, 155-168.	2.4	44
25	The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells. Translational Research, 2007, 150, 51-57.	5.0	33
26	Ontogeny of drug elimination by the human kidney. Pediatric Nephrology, 2006, 21, 160-168.	1.7	125